|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-09
|
$714,423
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
1/2 Langston University- UNTHSC Partnership for Cancer Research and Education
|
1P20CA233391-01
|
$210,731
|
QUINN, BYRON
|
LANGSTON UNIVERSITY
|
|
1/2 NCCU-DUKE Cancer Disparities Translational Research Partnership
|
5P20CA202924-03
|
$190,920
|
WILLIAMS, KEVIN
|
NORTH CAROLINA CENTRAL UNIVERSITY
|
|
1/2 U-HAND (University of Houston/MD Anderson) Program to Reduce Cancer Disparities
|
3P20CA221697-01S1
|
$47,364
|
REITZEL, LORRAINE
|
UNIVERSITY OF HOUSTON
|
|
1/2 U-HAND (University of Houston/MD Anderson) Program to Reduce Cancer Disparities
|
3P20CA221697-02S1
|
$142,991
|
REITZEL, LORRAINE
|
UNIVERSITY OF HOUSTON
|
|
1/2 U-HAND (University of Houston/MD Anderson) Program to Reduce Cancer Disparities
|
5P20CA221697-02
|
$310,904
|
REITZEL, LORRAINE
|
UNIVERSITY OF HOUSTON
|
|
1/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
|
1U54CA233396-01
|
$1,008,781
|
REAMS, ROMONIA
|
FLORIDA AGRICULTURAL AND MECHANICAL UNIV
|
|
2/2 Langston University-UNTHSC Partnership for Cancer Research and Education
|
1P20CA233355-01
|
$255,958
|
VISHWANATHA, JAMBOOR
|
UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
|
|
2/2 NCCU-DUKE Cancer Disparities Translational Research Partnership
|
3P20CA202925-03S1
|
$104,165
|
PATIERNO, STEVEN
|
DUKE UNIVERSITY
|
|
2/2 NCCU-DUKE Cancer Disparities Translational Research Partnership
|
5P20CA202925-03
|
$278,348
|
PATIERNO, STEVEN
|
DUKE UNIVERSITY
|
|
2/2 NCCU-LCCC Partnership in Cancer Research
|
5U54CA156733-09
|
$1,003,901
|
EARP, HENRY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
2/2 U-HAND (University of Houston/MD Anderson) Program to Reduce Cancer Disparities
|
3P20CA221696-02S1
|
$122,850
|
MCNEILL, LORNA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
2/2 U-HAND (University of Houston/MD Anderson) Program to Reduce Cancer Disparities
|
5P20CA221696-02
|
$222,707
|
MCNEILL, LORNA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
2/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
|
1U54CA233444-01
|
$1,054,795
|
ODEDINA, FOLAKEMI
|
UNIVERSITY OF FLORIDA
|
|
2/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
5U54CA118623-13
|
$1,101,004
|
TROY, ROBERTA
|
TUSKEGEE UNIVERSITY
|
|
3/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
|
1U54CA233465-01
|
$1,141,251
|
CARPTEN, JOHN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
5U54CA118948-13
|
$1,170,535
|
MANNE, UPENDER
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
3D Prostate Histochemometry to Predict Disease Recurrence
|
5R01CA197516-03
|
$400,610
|
BHARGAVA, ROHIT
|
UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
|
|
A blood test to identify prostate cancer patients at risk for visceral metastasis
|
5R01CA218356-02
|
$601,750
|
POSADAS, EDWIN
|
CEDARS-SINAI MEDICAL CENTER
|
|
A Mitogen-induced G Protein-coupled Receptor
|
ZIA SC 009389
|
$154,883
|
Kelly Siebenlist, Kathleen
|
CCR (NCI)
|
|
A Multilevel Intervention to Increase the Participation of African Americans in Prostate Cancer Clinical Trials
|
5R01CA200718-03
|
$665,635
|
EGGLY, SUSAN
|
WAYNE STATE UNIVERSITY
|
|
A New Mechanism for Castration Resistant Prostate Cancer
|
5R01CA166894-06
|
$368,984
|
SUN, ZIJIE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A new technique to make 68Ga-labeled pharmaceuticals widely available for clinical use
|
7R01CA207645-03
|
$575,548
|
OSBORNE, JOSEPH
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
A NOVEL SMALL MOLECULE CX3CR1 ANTAGONIST HALTS METASTASIS
|
5R44CA183362-03
|
$789,107
|
SALVINO, JOSEPH
|
ALLIANCE DISCOVERY, INC.
|
|
A Patient-Centered Approach to Integration of Life Expectancy into Treatment Decision Making for Patients with Genitourinary Malignancy
|
1K08CA230155-01
|
$183,258
|
DASKIVICH, TIMOTHY
|
CEDARS-SINAI MEDICAL CENTER
|
|
A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABR
|
5R01CA200551-03
|
$244,801
|
PARK, SEAN
|
MAYO CLINIC ROCHESTER
|
|
A Phase II trial of abiraterone in combination with PDMX1001 in enzalutamide-resistant prostate cancer
|
2R44CA206668-02A1
|
$754,319
|
LIU, CHENGFEI
|
PANDOMEDX, INC.
|
|
A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors
|
5R21CA198237-03
|
$79,570
|
DANHAUER, SUZANNE
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
A Target-Directed Reagent Pipeline via Microfluidic mRNA Display
|
5R21CA204708-02
|
$191,186
|
MALMSTADT, NOAH
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
|
1R01CA226537-01
|
$673,092
|
PASQUALINI, RENATA
|
RBHS -CANCER INSTITUTE OF NEW JERSEY
|
|
AARP prospective study of diet and cancer
|
ZIA CP010196 03152
|
$477,453
|
Sinha, Rashmi
|
DCEG (NCI)
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S1
|
$244,519
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S2
|
$55,717
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S3
|
$65,235
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-42
|
$7,716,753
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Academic-Industrial Partnership for Translation of PET/TRUS Guided Intervention
|
5R01CA204254-02
|
$135,982
|
FEI, BAOWEI
|
EMORY UNIVERSITY
|
|
ACADEMIC-INDUSTRIAL PARTNERSHIP FOR TRANSLATION OF PET/TRUS GUIDED INTERVENTION
|
7R01CA204254-03
|
$168,985
|
FEI, BAOWEI
|
UNIVERSITY OF TEXAS DALLAS
|
|
Activatable molecular cancer imaging probe
|
ZIA BC 011512
|
$125,971
|
Kobayashi, Hisataka
|
CCR (NCI)
|
|
Active surveillance and patient reported outcomes in a diverse population of prostate cancer patients
|
5R01CA211141-02
|
$624,859
|
GOMEZ, SCARLETT
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Adaptive resistance to HIF1a inhibition in hypoxia
|
5R01CA207377-03
|
$352,269
|
QIAN, ZHENG DAVID
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
Administrative Supplement to Cancer Center Support Grant to Support Acquisition and Annotation of Biospecimens
|
3P30CA022453-36S5
|
$46,200
|
BEPLER, GEROLD
|
WAYNE STATE UNIVERSITY
|
|
Advanced statistical modeling and analytics for prostate cancer interventions
|
5R50CA221836-02
|
$202,176
|
GULATI, ROMAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Aggressive Prostate Cancer: Linking Epigenomics and Genetics for Prevention
|
5K05CA175147-05
|
$88,959
|
STANFORD, JANET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Agricultural Cohort Consortium
|
ZIA CP010119 10537
|
$45,135
|
Beane Freeman, Laura
|
DCEG (NCI)
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S1
|
$3,249,644
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S2
|
$1,000,000
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-05
|
$8,073,787
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alteration of the miR-let-7c:Lin28 ratio as a predictor of therapy resistance in Prostate Cancer
|
5R03CA198696-02
|
$76,750
|
NADIMINTY, NAGALAKSHMI
|
UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS
|
|
An inevitable mechanism of resistance to androgen-directed therapy
|
5R01CA188609-05
|
$312,288
|
DONG, YAN
|
TULANE UNIVERSITY OF LOUISIANA
|
|
Analysis of Blood Borne Markers in Hormone Sensitive Metastatic Prostate Cancer
|
5R01CA208254-03
|
$519,293
|
SWEENEY, CHRISTOPHER
|
DANA-FARBER CANCER INST
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|